Markets:

Overview

News

Currencies

International

Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

37.35 +0.94 (+2.58%)

Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

29 30 Next >

The Oral Revolution: Novo Nordisk’s High-Stakes Bet on the Wegovy Pill

Today 10:07 EST

Introduction As of December 25, 2025, the global pharmaceutical landscape is witnessing a seismic shift centered on a single Danish company: Novo Nordisk (NYSE: NVO). Long the undisputed king of the...

Via PredictStreet

The Trillion-Dollar Pharma: A Deep Dive into Eli Lilly’s (LLY) Dominance in the Weight-Loss Era

Today 9:51 EST

As of December 25, 2025, the global pharmaceutical landscape has been fundamentally reshaped by a single entity: Eli Lilly and Company (NYSE: LLY). In a year defined by breakthrough medical treatments...

Via PredictStreet

Topics Economy Government Intellectual Property

Eli Lilly, Novo Nordisk Or A Dark Horse: Which Obesity-Drug Stock Are Retail Traders Most Bullish On Over Next 5 Years? ↗

November 06, 2025

Via Stocktwits

The Weight of Innovation: Eli Lilly’s Dominance in the GLP-1 Era

December 24, 2025

Date: December 24, 2025By: Financial Research Insights Introduction As 2025 draws to a close, few companies have dominated the financial and medical headlines as consistently as Eli Lilly and Company...

Via PredictStreet

Topics Economy

Novo Nordisk Stock Soars as "Wegovy Pill" Gains FDA Approval, Reshaping Obesity Market

December 23, 2025

Shares of Novo Nordisk (NYSE: NVO) surged more than 8% in early trading on December 23, 2025, after the pharmaceutical giant secured a landmark FDA approval for its high-dose oral semaglutide, branded...

Via MarketMinute

The Great Rotation: Small-Caps Break All-Time Highs as Investors Pivot from Mega-Tech

December 19, 2025

NEW YORK — In a dramatic shift that has redefined the market landscape of 2025, small-cap stocks have surged to historic levels, signaling what many analysts are calling the "Great Rotation." On...

Via MarketMinute

Topics Artificial Intelligence Economy Initial Public Offering

The Great Rotation: Why the Russell 2000 is Finally Outpacing the Giants in Late 2025

December 18, 2025

As of mid-December 2025, the long-awaited "Great Rotation" in the financial markets has shifted from a theoretical prediction to a dominant reality. For the better part of the last three years,...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

Eli Lilly’s Oral Obesity Drug Passes Maintenance Test After Wegovy, Zepbound — Wall Street Flags Win For Viking Therapeutics ↗

December 18, 2025

Lilly’s Orforglipron is eligible for a fast-track review by the FDA in treating obesity.

Via Stocktwits

2 Growth Stocks to Invest $1,000 in Right Now ↗

December 18, 2025

These stocks have promising assets in their portfolios that could help make their valuations soar in the future.

Via The Motley Fool

1 Bold Prediction for Viking Therapeutics in 2026 ↗

December 16, 2025

Viking's pipeline may release its value next year, and larger companies are likely to consider acquiring it.

Via The Motley Fool

2 Monster Stocks in the Making to Buy and Hold ↗

December 16, 2025

The next 12 months will tell us more about their prospects.

Via The Motley Fool

My Top 10 Stocks to Buy for 2026 ↗

December 13, 2025

These players are well-positioned to potentially gain next year -- and over time.

Via The Motley Fool

Topics Artificial Intelligence

3 Underrated Growth Stocks That Look Like Great Buys Heading Into 2026 ↗

December 11, 2025

These stocks are underperforming the market this year, but that trend may not last for long.

Via The Motley Fool

Topics Artificial Intelligence ETFs

What's Up With The Jump In Viking Therapeutics Stock? ↗

December 04, 2025

Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading higher on Thursday. The clinical-stage biopharmaceutical company seems to be benefitting from the wider excitement in obesity treatment area and...

Via Benzinga

Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029 ↗

November 27, 2025

The mid-cap biotech could become a notable player in the industry's hottest therapeutic area.

Via The Motley Fool

Retail Traders Crown Novo Nordisk As Long-Term Weight Loss King — Even As Eli Lilly Hits $1T And Viking Fans Tout ‘M&A Prize’ ↗

November 25, 2025

Users pointed to emerging drug pipelines, GLP-1 expansion and rising M&A pressure across the sector.

Via Stocktwits

2 Healthcare Stocks for Beginner Investors With a 20-Year Time Horizon ↗

November 22, 2025

For those with decades left in their investing journey, these top healthcare stocks could be worthy portfolio contenders.

Via The Motley Fool

Topics Intellectual Property

3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential ↗

November 21, 2025

These stocks have market caps of around $4 billion and $5 billion, and they could potentially double or triple in size in the long run.

Via The Motley Fool

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗

November 19, 2025

These stocks both have advanced in the double-digits in recent months.

Via The Motley Fool

5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity? ↗

November 18, 2025

One major biotech investor just walked away from Viking Therapeutics. Here’s what the move may—and may not—mean for the company’s clinical-stage future.

Via The Motley Fool

Topics Regulatory Compliance

2 No-Brainer Healthcare Stocks to Buy Now ↗

November 18, 2025

These two healthcare stocks scan as bargains right now.

Via The Motley Fool

Druckenmiller Opens Position In Amazon, Closes Microsoft — Here's More Of Duquesne's Biggest Q3 Moves ↗

November 14, 2025

Stanley Druckenmiller's Duquesne Family Office Q3 13F reinforces the firm's reputation for agile and opportunity-driven asset allocation.

Via Benzinga

Viking Therapeutics Stock Soars To 10-Month High After Canaccord Boost – Retail Traders See It As Next Big Obesity Play ↗

November 13, 2025

Canaccord said Viking’s obesity pipeline is worth far more than the current valuation.

Via Stocktwits

‘Somebody Knows Something:’ Viking Therapeutics Stock Pops To Nearly 3-Month High As Retail Traders Intensely Speculate On M&A Scenarios ↗

November 11, 2025

Via Stocktwits

AMD, Oklo, AppLovin Corp, Viking Therapeutics And Novo Nordisk: Why These 5 Stocks Are On Investors' Radars Today ↗

November 11, 2025

Major U.S. indices closed mixed on Tuesday, with the Dow Jones Industrial Average climbing 1.2% to 47,927.96 and the S&P 500 inching up 0.2% to 6,846.61.

Via Benzinga

Topics Stocks

2 Monster Stocks in the Making ↗

November 10, 2025

There might still be time to get in on the ground floor.

Via The Motley Fool

Novo Nordisk Loses Metsera Bidding War To Pfizer — But Retail Traders Aren’t Losing Faith ↗

November 09, 2025

Novo investors on Stocktwits praised new CEO Mike Doustdar as “dynamic,” saying they remain confident in Novo’s long-term obesity and diabetes pipeline despite short-term setbacks.

Via Stocktwits

Is There a Future for Viking Therapeutics? ↗

November 09, 2025

The weight loss drug company was counted out far too early in the summer, but investors are warming to it again.

Via The Motley Fool

The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things. ↗

November 07, 2025

The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned.

Via Investor's Business Daily

Topics Government

Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain ↗

November 05, 2025

Stanley Druckenmiller's firm bought Viking Therapeutics stock (VKTX) during Q2 at $25.33. Now up 36%, VKTX shows a Golden Cross.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.